Telix has assembled a portfolio of promising molecularly targeted radiation (MTR) therapeutic and imaging products for three different cancers. Each product has been validated by clinical studies or compassionate use in patients, thus reducing development risk. Telix is positioned to add significant value, such as by refining the products or developing them as a combination therapy. Preparations for a confirmatory Phase III study for kidney cancer imaging agent TLX250-CDx and for multiple Pha
20 Aug 2018
Telix Pharmaceuticals - Targeted radiation to image and treat cancer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Telix Pharmaceuticals - Targeted radiation to image and treat cancer
Telix Pharmaceuticals Ltd. (TLX:ASX) | 0 0 0.0%
- Published:
20 Aug 2018 -
Author:
Dr Dennis Hulme -
Pages:
24
Telix has assembled a portfolio of promising molecularly targeted radiation (MTR) therapeutic and imaging products for three different cancers. Each product has been validated by clinical studies or compassionate use in patients, thus reducing development risk. Telix is positioned to add significant value, such as by refining the products or developing them as a combination therapy. Preparations for a confirmatory Phase III study for kidney cancer imaging agent TLX250-CDx and for multiple Pha